Chagas Disease: What U.S. Clinicians Need to Know
This course is designed to educate clinicians about Chagas disease in the United States. Lesson 1 covers basic epidemiology, including a detailed life cycle of Trypanosoma cruzi (the causative agent) and risk factors for acquiring the disease. Lesson 2 discusses phases and manifestations of Chagas disease. Lesson 3 covers laboratory diagnosis, clinical evaluation, and treatment options. This course also includes 3 patient scenarios, to present an opportunity to think critically about diagnosis and treatment of Chagas disease.
For Continuing Medical Education for Physicians (CME):
The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this educational activity for a maximum of (1.25) AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Education designated for Non-Physicians:
Non-physicians will receive a certificate of participation.
Continuing Nursing Education for Nurses (NE)
The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity provides (1.0) contact hours.
Instructions for Completing Posttest & Evaluation Online
This course will expire September 1, 2016.
The author of this course is Caryn Bern, MD, MPH of the Division of Parasitic Diseases and Malaria. Developers of this course are Sharon Hall, PhD, RN, Susan P. Montgomery, DVM, MPH, and Kelly Stimpert, MPH.
For assistance with registration, completing the course assessment and posttest, transcripts, and printing continuing education certificates, please contact OWCD Training and Continuing Education. OWCD can be reached via:
Please email email@example.com with any questions regarding this course.
CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Susan Montgomery, DVM, MPH, and Dana Woodhalls, MD's discussion on nifurtimox and benznidazole, two drugs used to treat infection with Trypanosoma cruzi. In the United States, these drugs are not FDA approved and are available only from CDC under investigative protocols. Investigational protocols are defined as legal provisions that allow for emergency distribution of unlicensed drugs, using strict inventory control and record keeping, along with completion of a signed consent form.
CDC does not accept commercial support.